Application of quinoxaline derivatives in the preparation of wound healing drugs

By using the quinoxaline derivative CA77.1 to enhance cell migration and invasion capabilities at extremely low concentrations, the problem of unsatisfactory wound healing effects in existing technologies has been solved, achieving rapid and safe wound healing, especially for chronic wounds in diabetic patients.

CN118161495BActive Publication Date: 2026-11-10EXPLORING HEALTH LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410306820.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-18
Publication Date
2026-11-10
Estimated Expiration
2044-03-18

AI Technical Summary

Technical Problem

Existing technologies are not very effective in promoting wound healing, especially chronic wound healing, particularly for diabetic patients, where delayed angiogenesis makes healing difficult, and existing drugs are difficult to develop and have uncontrollable cytotoxicity.

Method used

The use of quinoxaline derivatives, especially N-(4-(6-chloroquinoxalin-2-yl)phenyl)acetamide (CA77.1), significantly enhances cell migration and invasion capabilities at extremely low concentrations, promotes wound healing, and is suitable for various wound types, including wound healing in diabetic patients.

Benefits of technology

It significantly improves cell motility at low concentrations, has high safety, rapidly promotes wound healing, and reduces the healing time of chronic wounds. It is suitable for external injuries, burns, ulcers, dermatitis, and childbirth wounds, and is especially effective for diabetic patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118161495B_ABST
    Figure CN118161495B_ABST
Patent Text Reader

Abstract

This invention relates to the application of a class of quinoxaline derivatives in the preparation of wound-healing drugs. The invention found that the quinoxaline derivative CA77.1, after treatment at concentrations below 2 μM for 24–48 h, exhibited significant migration and invasion activity against human foreskin fibroblasts (HFF-1), indicating that CA77.1 can rapidly improve cell motility. Simultaneously, the quinoxaline derivative CA77.1 of this invention showed no drug toxicity trend against human foreskin fibroblasts (HFF-1) and mouse embryonic fibroblasts (L-929) at a concentration of 100 μM / L, demonstrating very high safety. Therefore, the quinoxaline derivatives provided by this invention can achieve safe and non-toxic wound-healing effects over a wide dosage range. Especially for diabetic patients with poor wound healing ability, the quinoxaline derivatives of this invention have a significant effect on reducing the healing time of chronic wounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical and formulation technology, specifically relating to the application of quinoxaline derivatives in the preparation of wound-healing drugs. Background Technology

[0002] As the largest organ in the human body, the skin plays a vital role in protecting organs and tissues, preventing infection, maintaining water and electrolyte balance, and regulating body temperature, while also maintaining the stability of the internal environment. However, the skin is also quite fragile and inevitably suffers trauma in daily life. Skin trauma not only causes pain and affects the patient's physical health, but facial skin trauma can also impact their psychological and mental well-being. Wound healing is an extremely complex and dynamic process, and how to effectively promote wound healing and prevent infection is an important topic in the field of wound repair. The self-repair and tissue regeneration of wounds are complex cellular processes involving the interactions between GFs, chemokines, cytokines, and other signaling molecules. The wound healing process is continuous and intersecting, and can be roughly divided into four phases: coagulation phase, inflammation phase, proliferation phase, and remodeling phase. Among them, the proliferation phase is the most critical phase, mainly involving keratinocytes, vascular endothelial cells, and fibroblasts. For the healing of chronic wounds, angiogenesis at this stage is exceptionally difficult. For example, in the wounds of diabetic patients, the process of angiogenesis is very slow, and the surface area of ​​blood vessels, the number of branch connections, the total length of blood vessels, and the total number of branches in the wound are all significantly reduced. Angiogenesis can effectively support wound closure, and vascular lesions are one of the causes of chronic wounds being difficult to heal.

[0003] Currently, wound and lesion treatments mainly include laser therapy, therapeutic dressings, negative pressure therapy, and skin grafting. However, these methods have many limitations in clinical application, especially for chronic wounds where their effectiveness is not ideal. Therefore, developing new drugs to accelerate wound healing, particularly for chronic wounds in patients with diabetes, is an urgent problem to be solved. Given the significant challenges in developing new drugs to promote wound healing, the relatively low wound-healing activity achieved, and the difficulty in controlling cytotoxicity, developing new uses for existing drugs remains a rapid and effective approach to drug development. Summary of the Invention

[0004] To address the aforementioned technical problems, this invention provides the application of quinoxaline derivatives in the preparation of wound-healing drugs. These quinoxaline derivatives can significantly enhance cell migration and invasion capabilities and can be used to promote wound healing in diabetic or non-diabetic patients.

[0005] In a first aspect, the present invention provides the application of quinoxaline derivatives in the preparation of wound-healing drugs, wherein the quinoxaline derivatives include the following molecular structural formulas:

[0006]

[0007] Preferably, the quinoxaline derivative is N-(4-(6-chloroquinoxalin-2-yl)phenyl)acetamide (CA77.1), and its molecular structural formula is as follows:

[0008]

[0009] Furthermore, the drug includes ingredients that promote wound and lesion healing in diabetic patients.

[0010] Furthermore, the drug includes features that promote wound and lesion healing in non-diabetic patients.

[0011] Secondly, the present invention also provides a wound-healing medicament comprising the quinoxaline derivative and its geometric isomers or pharmaceutically acceptable salts thereof and / or solvates thereof and / or hydrates thereof.

[0012] Furthermore, the drug also includes pharmaceutically acceptable excipients.

[0013] Furthermore, the dosage forms of the drug include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, drops, or liniments, and other indications not listed above within the above dosage form range also apply.

[0014] Furthermore, the drug includes ingredients that promote wound and lesion healing in diabetic patients.

[0015] The indications for the drug include wounds and lesions in diabetic patients or in non-diabetic patients, but are not limited to the indications listed above. Other indications not listed above are also applicable.

[0016] Furthermore, the wounds of non-diabetic patients include burns, scalds, ulcers, dermatitis, and those caused by childbirth, but are not limited to the indications listed above. Other unlisted indications within the scope of the above indications also apply.

[0017] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0018] This invention develops novel applications for quinoxaline derivatives, discovering that these derivatives can promote cell migration and invasion, particularly showing significant effects on the migration and invasion of human foreskin fibroblasts (HFF-1). Specifically, compound CA77.1 exhibits significant activity against the migration and invasion of HFF-1 cells at concentrations below 2 μM. Therefore, this invention demonstrates that quinoxaline derivatives can significantly enhance the motility of HFF-1 cells at extremely low concentrations, thereby improving cell migration, invasion, and penetration capabilities. Furthermore, this invention utilizes quinoxaline... The derivative CA77.1 showed no drug toxicity trend against human foreskin fibroblasts HFF-1 and mouse embryonic fibroblasts L-929 at a concentration of 100 μm / L, indicating very high safety. It is evident that the quinoxaline derivatives provided by this invention can rapidly enhance cell motility over a wide dosage range, thereby promoting wound healing and accelerating healing. Especially for diabetic patients with poor wound healing ability, it can further reduce the healing time of chronic wounds and can be widely applied to promote the healing of external injuries, burns, ulcers, dermatitis, chronic wounds, and childbirth wounds. Attached Figure Description

[0019] Figure 1 This study presents an in vitro toxicity experiment of the quinoxaline derivative CA77.1 of this invention on human foreskin fibroblasts HFF-1.

[0020] Figure 2 This invention provides an in vitro toxicity experiment of the quinoxaline derivative CA77.1 on mouse embryonic fibroblast L-929 cells.

[0021] Figure 3 This is a migration diagram of the quinoxaline derivative CA77.1 of the present invention on human foreskin fibroblasts HFF-1.

[0022] Figure 4 This is a statistical result of the data on the migration of human foreskin fibroblasts HFF-1 by the quinoxaline derivative CA77.1 of this invention.

[0023] Figure 5 This is a diagram showing the invasion of the quinoxaline derivative CA77.1 of this invention into human foreskin fibroblasts HFF-1.

[0024] Figure 6 This is a statistical result of the data on the invasion of human foreskin fibroblasts HFF-1 by the quinoxaline derivative CA77.1 of this invention. Detailed Implementation

[0025] Unless otherwise specified, the experimental methods described in the following embodiments of the present invention are generally performed under conventional conditions or as recommended by the manufacturer. All commonly used chemical reagents used in the embodiments are commercially available products.

[0026] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention.

[0027] The terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, apparatus, product, or device that includes a series of steps is not limited to the steps or modules listed, but may optionally include steps not listed, or may optionally include other steps inherent to such process, method, product, or device.

[0028] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that these descriptions are merely exemplary and not intended to limit the scope of the invention. Furthermore, descriptions of well-known structures and technologies are omitted in the following description to avoid unnecessarily obscuring the concepts of the invention.

[0029] The following embodiments further describe the present invention, but these embodiments are not intended to limit the scope of protection of the present invention.

[0030] In a specific embodiment of the present invention, N-(4-(6-chloroquinoxalin-2-yl)phenyl)acetamide (CA77.1) was used for experiments, and its molecular structure is as follows:

[0031]

[0032] Example 1: CCK8 Cytotoxicity Assay

[0033] (1) Experimental subjects: human foreskin fibroblasts HFF-1 and mouse embryonic fibroblasts L-929;

[0034] (2) Experimental reagents: compound CA77.1, solvent DMSO (dimethyl sulfoxide);

[0035] (3) Experimental methods:

[0036] On the afternoon of the first day, the cells were plated: Log-phase cells were collected, the cell suspension concentration was adjusted, and 90uL of 5000 human foreskin fibroblasts (HFF-1) and 8000 mouse embryonic fibroblasts (L-929) were added to each well.

[0037] The next morning, add 10 μL of drug at different concentrations to each well, with three replicates for each drug concentration. Incubate in a 5% CO2 incubator at 37°C.

[0038] Collect the plate 48 hours after adding the drug: first observe it with the naked eye under an inverted microscope, then add 10 μL of LCK8 solution to each well, incubate at 37°C for 1 hour, and then terminate the reaction.

[0039] OD value detection: The absorbance of each well was detected at a wavelength of 450nm using an ELISA reader. The relative cell viability or drug inhibition rate was calculated according to formulas (1) and (2), in %;

[0040]

[0041] Drug inhibition rate % = 1 - relative survival rate % (2)

[0042] In this experiment, cell-free culture medium was used as a blank control group, DMSO solution with the same dilution ratio as compound CA77.1 was added to each well as a negative control group, and compound CA77.1 was used as the compound experimental group.

[0043] The effects of compound CA77.1 on the growth activity of human foreskin fibroblasts HFF-1 and mouse embryonic fibroblasts L-929 were tested using the above experimental method (CCK8 toxicity test, 48 h). The results are shown in the figure. Figure 1 and Figure 2 At concentrations below 100 μm / L, compound CA77.1 showed virtually no toxicity to human foreskin fibroblasts (HFF-1) and mouse embryonic fibroblasts (L-929), and its IC50 was undetectable. 50 .

[0044] Example 2: Cell migration ability experiment (cell scratch assay)

[0045] (1) Experimental subject: human foreskin fibroblasts HFF-1;

[0046] (2) Experimental reagents: compound CA77.1, solvent DMSO (dimethyl sulfoxide);

[0047] (3) Experimental methods:

[0048] Before plating, use the fine tip of a marker pen to draw evenly horizontal lines on the back of the 6-well plate, approximately every 0.5–1 cm, across each well. Generally, draw three lines, named a, b, and c. Line b crosses the center, and the other two lines are drawn at equal intervals on either side of line b. After plating the 6-well plate, add 2 mL of complete culture medium containing 10% FBS (fetal bovine serum) to each well. (2 × 10⁶) 6Each well contains 10 cells, with two replicates. Culture for approximately 24 hours, ensuring at least 90% cell adhesion overnight. Adjust as needed. The next day, open the plate, remove the old culture medium, and place a ruler perpendicular to line b on the plate. Use a 200µL pipette tip to create cell scratch lines by moving it evenly up and down along the ruler. Similarly, draw two parallel lines at equal intervals on either side of the first line, naming them line 1, line 2, and line 3 from left to right. Rinse the cells three times with sterile 1×PBS (phosphate-buffered saline diluted 1 times). Remove the scratched cells, add complete culture medium containing 10% FBS (fetal bovine serum), and then add compound CA77.1 (working concentrations of 1μM and 2μM). Incubate at 37°C in a 5% CO2 incubator. Take samples and photographs at 0h and 24h after drug addition.

[0049] The transfer ability experiment was conducted using the experimental method described above, and the results are shown below. Figure 3 and Figure 4 The experimental results showed that, compared with the control group (DMSO solution), low concentrations (1 μM, 2 μM) of compound CA77.1 significantly improved the motility and migration of human fibroblast HFF-1 cells and promoted wound healing after 24 h of treatment. *** indicates P<0.001, indicating that there was a significant difference between the untreated control group and the treated group (concentrations of 1 μm / L and 2 μm / L).

[0050] Example 3: Cell migration ability experiment (Transwell assay for cell invasion)

[0051] (1) Experimental subject: human foreskin fibroblasts HFF-1;

[0052] (2) Experimental reagents: compound CA77.1, solvent DMSO (dimethyl sulfoxide);

[0053] (3) Experimental methods:

[0054] Preparation of cell suspension: Digest cells, stop digestion, centrifuge and discard culture medium, wash once with PBS (phosphate buffered PBS), resuspend in serum-free culture medium, and adjust cell density to an appropriate concentration (the seeding density of human foreskin fibroblasts HFF-1 is 1×10⁻⁶). 5 (each 200μL);

[0055] Cell seeding: For each cell type, a negative control group (containing DMSO at the same dilution ratio as compound CA77.1) and a drug treatment group (containing 0.1 μM and 0.2 μM of compound CA77.1 for human foreskin fibroblasts HFF-1) were set up, with 3 replicates for each group. According to the cell density, an appropriate amount of cell suspension was taken, and an appropriate volume of 10% BSA was added to make the final percentage 0.1%. Then, compound CA77.1 was added, and finally, DMEM was used to make the total volume of each well 200 μL. After mixing, the mixture was gently and evenly added to the upper chamber of the Transwell plate. Immediately afterward, 800 μL of medium containing 20% ​​FBS was added to the lower chamber of the 24-well plate. The plate was collected after about 48 hours of drug treatment.

[0056] Cell staining: Remove the Transwell chamber, discard the culture medium in the well, gently wipe away the unmigrated cells in the upper chamber with a cotton swab, and place it into a clean 24-well plate. Wash once with 1×PBS, fix with methanol for 30 minutes, remove the methanol, air dry the chamber in a fume hood, stain with 0.1% crystal violet for 20 minutes, remove and recover the crystal violet, wash once with PBS, remove the PBS, and air dry in a fume hood.

[0057] Results: Cells were observed under a 5X microscope and five random fields of view under a 10X microscope. Photos were taken, counts were recorded, and graphs were plotted. See below for results. Figure 5 and Figure 6 Compound CA77.1 at low concentrations of 0.1 μM and 0.2 μM significantly promoted the migration and invasion of human foreskin fibroblasts HFF-1. *** indicates P < 0.001, showing a significant difference between the untreated control group and the treated group (concentrations of 0.1 μm / L and 0.2 μm / L), indicating that compound CA77.1 can promote wound healing, improve wound healing ability, and accelerate wound healing speed.

[0058] It should be noted that the specific features, structures, materials or characteristics described in this specification can be combined in any way. For the sake of brevity, not all possible combinations of the various technical features in the above embodiments have been described. Without contradiction, those skilled in the art can combine and integrate the different embodiments and features described in this specification.

[0059] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. The application of quinoxaline derivatives in the preparation of wound-healing drugs, characterized in that, The molecular structural formula of the quinoxaline derivative is as follows: ; The drug's indications include wounds in diabetic patients or wounds in non-diabetic patients; The wounds of non-diabetic patients include those caused by burns, scalds, ulcers, dermatitis, and childbirth.

2. The application of the quinoxaline derivative according to claim 1 in the preparation of wound-healing drugs, characterized in that, The drug also includes pharmaceutically acceptable excipients.

3. The application of the quinoxaline derivative according to claim 1 in the preparation of wound-healing drugs, characterized in that, The dosage forms of the drug include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, drops, or liniments.

Citation Information

Patent Citations

  • Use of isoquinoline derivatives for diabetic wound healing

    CN107427508A

  • Compounds useful as chaperone-mediated autophagy modulators

    CN112714761A